Curanex Pharmaceuticals Common Stock

CURX | NASDAQ

$5.20

+$0.04 (+0.78%)

Nov 2, 2026, 9:34 AM ET · Market open

TTM Period Ending	Q2 2026 Jun 30, 2026	Q1 2026 Mar 31, 2026	Q4 2025 Dec 31, 2025	Q3 2025 Sep 30, 2025	Q2 2025 Jun 30, 2025	Q1 2025 Mar 31, 2025	Q2 2024 Jun 30, 2024
Net Income	-10.47M	-7.24M	-4.23M	-1.15M	-197.93K	-181.78K	-44.2K
Depreciation & Amortization	121.41K	99.8K	79.4K	45.1K	29.66K	14.63K	n/a
Stock-Based Compensation	9.79K	9.79K	n/a	n/a	n/a	n/a	n/a
Other Working Capital	-1.86M	-4.16M	-6.45M	-8.74M	-267.03K	-340.18K	-192.13K
Other Non-Cash Items	113.94K	119.91K	113.94K	113.94K	n/a	n/a	n/a
Deferred Income Tax	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Change in Working Capital	-1.86M	-4.28M	-6.45M	-8.63M	-271.76K	-219.13K	-192.13K
Operating Cash Flow	-12.08M	-11.29M	-10.48M	-9.63M	-440.03K	-386.28K	-236.33K
Capital Expenditures	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Cash Acquisitions	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Purchase of Investments	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Sales Maturities Of Investments	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Other Investing Acitivies	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Investing Cash Flow	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Debt Repayment	-400K	-200K	n/a	n/a	400K	200K	n/a
Common Stock Repurchased	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Dividend Paid	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Other Financial Acitivies	-346.5K	-346.5K	-346.5K	-346.5K	n/a	100	100
Financial Cash Flow	14.91M	15.11M	15.31M	15.31M	400K	780.1K	580.1K
Net Cash Flow	2.83M	3.82M	4.82M	5.68M	-40.03K	393.82K	343.77K
Free Cash Flow	-12.08M	-11.29M	-10.48M	-9.63M	-440.03K	-386.28K	-236.33K
Adj. Free Cash Flow	-12.09M	-11.3M	-10.48M	-9.63M	-440.03K	-386.28K	-236.33K
Maintenance CapEx	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Growth CapEx	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Owner Earnings	-12.08M	-11.29M	-10.48M	-9.86M	n/a	n/a	n/a